Seelos Therapeutics Inc
NASDAQ:SEEL
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.6775
  • TODAY'S CHANGE (%)
    -0.0425 (-5.9028%)
  • Bid / Lots
    0.7113/ 15
  • Ask / Lots
    0.7200/ 1
  • Open / Previous Close
    0.7300 / 0.7200
  • Day Range
    0.6750
    0.7400
  • 52 Week Range
    0.4803
    1.5200
  • Volume
    646,820

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Line Graph See accessible table below

  • Mar 10, 2023

      Show headlines and story abstract

    • 4:01PM ET on Friday Mar 10, 2023 by MT Newswires
      Companies Mentioned: SEEL, MTEM, BNGO, CRBU
      04:01 PM EST, 03/10/2023 (MT Newswires) -- Health care stocks were moderately lower compared with most industry sectors ahead of Friday's closing bell, with the NYSE Health Care Index declining 0.7% while the Health Care Select Sector SPDR Fund (XLV...

    • 2:21PM ET on Friday Mar 10, 2023 by MT Newswires
      Companies Mentioned: SEEL, MTEM, CRBU
      02:21 PM EST, 03/10/2023 (MT Newswires) -- Health care stocks were moderately lower compared with most industry sectors this afternoon, with the NYSE Health Care Index sinking 0.8% while the Health Care Select Sector SPDR Fund (XLV) was down 0.9%. ...

    • 10:38AM ET on Friday Mar 10, 2023 by MT Newswires
      Companies Mentioned: SEEL
      10:38 AM EST, 03/10/2023 (MT Newswires) -- Seelos Therapeutics (SEEL) said Friday it struck a deal with an investment fund to sell about 12 million shares, pre-funded warrants exercisable for about 9.3 million shares and common warrants exercisable ...

    • 9:00AM ET on Friday Mar 10, 2023 by PR Newswire
      Companies Mentioned: SEEL

      Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today it has entered into an agreement with a life sciences-focused investment fund for the sale of 12,059,298 shares of its common stock, pre-funded warrants exercisable for an aggregate of 9,340,702 shares of common stock and common warrants exercisable for an aggregate of 26,750,000 shares of common stock. The shares of common stock and accompanying common warrants are being sold at a combined offering price of $0.525 per share, and the pre-funded warrants and accompanying common warrants are being sold at a combined offering price of $0.524 per pre-funded warrant. All of the shares of common stock, pre-funded warrants and accompanying warrants to be sold in the offering will be sold by Seelos. The pre-funded warrants will be immediately exercisable following the closing of the offering and will have an exercise price of $0.001 per share. The common warrants will not be exercisable until after the six-month anniversary of the closing of the offering, will have an exercise price of $0.60 per share and will expire on the date that is five and a half years following the closing of the offering.

Peers Headlines